Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 15 recruiting now official registry

Stage IV Prostate Cancer AJCC v8 clinical trials

15 of 29 indexed Stage IV Prostate Cancer AJCC v8 trials are currently recruiting.

29 US clinical trials · 15 currently recruiting

Stage IV Prostate Cancer AJCC v8 is the subject of 29 registered US clinical trials on ClinicalTrials.gov, 15 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 24 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 6 of these trials.

The research picture

Stage IV Prostate Cancer AJCC v8 has 29 registered US clinical trials, 15 of them open to new participants right now, about 52% of the total.

15
recruiting participants now
52%
of trials open to enrollment
3
in Phase 3–4 (later-stage)
6
top sponsor: M.D. Anderson Cancer Center
Phase 15Phase 219Phase 33

Active & Recent Trials

29 total, page 1 of 1

RECRUITING Phase 3 1,273 participants

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

SWOG Cancer Research Network

NCT03678025

RECRUITING Early Phase 1 220 participants

Immunological Effects of Vitamin D Replacement Among Black/African American Prostate Cancer Patients

Mayo Clinic

NCT05045066

RECRUITING Phase 2 210 participants

Bright White Light Therapy in Reducing Cancer-Related Fatigue and Depression in Advanced Prostate Cancer Patients Undergoing Treatment With ADT Combination Therapy

City of Hope Medical Center

NCT05869682

RECRUITING Phase 2 200 participants

Modifying Metabolic Syndrome and Cardiovascular Risk for Prostate Cancer Patients on ADT Using a Risk Factor Modification Program and Continuous Fitbit Monitoring

M.D. Anderson Cancer Center

NCT05054296

RECRUITING NA 120 participants

Peer Navigation for the Support of Metastatic Prostate Cancer Patients Undergoing Genetic Evaluation

Thomas Jefferson University

NCT05487846

RECRUITING Phase 3 118 participants

SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma

Mayo Clinic

NCT06205316

RECRUITING Phase 2 102 participants

Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy

Jonsson Comprehensive Cancer Center

NCT04915508

RECRUITING Phase 2 75 participants

Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer

University of California, Davis

NCT06173362

RECRUITING Phase 2 70 participants

Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer

City of Hope Medical Center

NCT04734730

RECRUITING Phase 2 38 participants

Evaluating In Home Cancer Therapy Versus In Clinic Cancer Therapy in Black Men With Locally Advanced, Biochemically Recurrent and Metastatic Prostate Cancer

Mayo Clinic

NCT07073794

RECRUITING Phase 2 33 participants

Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial

University of Utah

NCT05168618

RECRUITING Phase 2 30 participants

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

National Cancer Institute (NCI)

NCT05691465

RECRUITING Phase 1 30 participants

Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer

Vadim S Koshkin

NCT05113537

RECRUITING Phase 2 30 participants

Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial

Mayo Clinic

NCT07025369

RECRUITING 30 participants

Extending Prostate Genetic Awareness, Navigation, and Delivery: The EXPAND Network

Thomas Jefferson University

NCT05627219

ACTIVE NOT RECRUITING Phase 1 173 participants

Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies

M.D. Anderson Cancer Center

NCT03217747

ACTIVE NOT RECRUITING Phase 2 120 participants

Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer

M.D. Anderson Cancer Center

NCT04592237

ACTIVE NOT RECRUITING Phase 2 84 participants

A Study to Evaluate Hypofractionated Proton Therapy or IMRT for Recurrent, Oligometastatic Prostate Cancer

Mayo Clinic

NCT04190446

ACTIVE NOT RECRUITING Phase 2 79 participants

Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM)

Alliance for Clinical Trials in Oncology

NCT05241860

ACTIVE NOT RECRUITING Phase 2 73 participants

M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

National Cancer Institute (NCI)

NCT03517969

ACTIVE NOT RECRUITING Phase 1 65 participants

DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers

M.D. Anderson Cancer Center

NCT04388852

ACTIVE NOT RECRUITING Phase 3 61 participants

A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy

Alliance for Clinical Trials in Oncology

NCT04455750

ACTIVE NOT RECRUITING Phase 2 61 participants

ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Rahul Aggarwal

NCT04471974

ACTIVE NOT RECRUITING Phase 2 60 participants

Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer

M.D. Anderson Cancer Center

NCT03821792

ACTIVE NOT RECRUITING Phase 2 15 participants

68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer

Thomas Hope

NCT04716725

ACTIVE NOT RECRUITING Phase 1 14 participants

PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer

City of Hope Medical Center

NCT03873805

ACTIVE NOT RECRUITING Phase 2 8 participants

Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study

University of Washington

NCT05960578

COMPLETED Phase 2 937 participants

68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer

Jonsson Comprehensive Cancer Center

NCT04050215

COMPLETED Phase 2 31 participants

Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer

M.D. Anderson Cancer Center

NCT03204812

Phase Distribution

PhaseTrial count
Phase 1 5
Phase 2 19
Phase 3 3

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

Reading the Stage IV Prostate Cancer AJCC v8 Trial Landscape

29 indexed Stage IV Prostate Cancer AJCC v8 studies · 15 recruiting (52%).

Phase mix: 3 late (III/IV) vs 24 early (I/II).

Top sponsor: M.D. Anderson Cancer Center (6 trials), 9 others listed. 29 shown below, recruiting first.

How to read this condition's trial landscape

That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.

Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.

All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation, eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.

Frequently Asked Questions

How many clinical trials are there for Stage IV Prostate Cancer AJCC v8?

PlainTrial tracks 29 US clinical trials for Stage IV Prostate Cancer AJCC v8, of which 15 are currently recruiting participants. Data sourced from ClinicalTrials.gov.

How do I find a recruiting trial for Stage IV Prostate Cancer AJCC v8?

Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.

Is this data current?

Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.

Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.

Verify with NIH →

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial for this condition, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.